United States: Medical reports show that the results of an experimental treatment can help patients whose high blood pressure remains out of control.
Scientific trials found that lorundrostat caused patients to experience a double reduction in their systolic blood pressure readings compared to those receiving a placebo, as per results published in the New England Journal of Medicine.
Hope for Treatment-Resistant Hypertension
Systolic pressure measures the blood vessel pressure peak that occurs at the same time as a heartbeat.
According to the principal investigator, Dr. Michael Wilkinson, an associate professor with the University of California-San Diego School of Medicine, “While blood pressure readings remained elevated at the end of this Phase II trial in some participants treated with lorundrostat, we find these results promising because almost all participants involved in the study were not able to sufficiently lower their blood pressure with medication before,” US News reported.
The research team explained in background statements that lorundrostat blocks aldosterone hormone synthesis, which scientists have identified as the primary cause of prolonged hypertension.
“We were specifically studying a new approach to addressing imbalanced aldosterone, which is an often underrecognized cause for treatment-resistant hypertension,” as Wilkinson noted.
A clinical trial accepted 285 patients with uncontrolled hypertension while using two to five blood pressure medications.
High blood pressure or hypertension exists when blood pressure reaches 130 systolic or higher combined with diastolic pressure at 80 or above, as documented by the American Heart Association.
Of the patients enrolled in the study, two-thirds received lorundrostat for 12 weeks, but the other third received a placebo, US News reported.
New Drug Shows Promise for Uncontrolled High Blood Pressure.
— BlinkCoPulse (@BlinkCoPulse) May 5, 2025
Clinical trial results indicate effectiveness in patients resistant to current treatments.
🔗 https://t.co/e1sJ3MMbBH#MedicalNews #HypertensionTreatment #BlinkcoPulse
Clinical Trial Shows Double Systolic Reduction
“Ultimately, we found that the therapy, compared to placebo, was helpful in lowering a person’s systolic blood pressure,” Wilkinson added.
Participants taking lorundrostat reduced their systolic blood pressure by an average of 15 points, whereas people on placebo medication recorded only a 7-point systolic pressure decrease.
The favorable findings obtained through this trial should advance toward a Phase III clinical study for lorundrostat to establish an FDA approval application, according to researchers.
“As we learn more about the safety and efficacy of this treatment, I’m hopeful we will identify a useful tool in addressing high blood pressure for patients in need,” Wilkinson concluded.